US Bancorp’s Checkpoint Therapeutics CKPT Stock Holding History

US Bancorp’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-22	Closed	-$70	–	4227
2024 Q4	$70	Buy	+22	New	+$75	﹤0.01%	4116

Other funds holding CKPT

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

GLF

Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

US Bancorp's CKPT Position: Q1 2025 in Review

US Bancorp sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 22 shares — an estimated $70 sold.

US Bancorp first reported a position in CKPT in Q4 2024 and held it in 1 quarter. The position peaked at $70 in Q4 2024. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

US Bancorp reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
US Bancorp sold 22 Checkpoint Therapeutics shares in Q1 2025, an estimated $70.
US Bancorp first reported a position in Checkpoint Therapeutics in Q4 2024 and held it in 1 quarter.
US Bancorp's Checkpoint Therapeutics position peaked at $70 in Q4 2024.
84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.